NCT02346747 2025-10-29
VITAL
Gradalis, Inc.
Phase 2 Active not recruiting
Clinical Trials
5 trialsNCT03073525 2023-04-05
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
Gradalis, Inc.
Phase 2 Completed
NCT02511132 2022-12-22
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Gradalis, Inc.
Phase 2 Completed
NCT02639234 2017-07-31
Vigilâ„¢ + Nivolumab in Advanced Non-Small Cell Lung Cancer
Gradalis, Inc.
Phase 2 Withdrawn
NCT00003715 2015-12-03
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
AVAX Technologies
Phase 2 Terminated